Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heald, A. H.
Right arrow Articles by Gibson, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heald, A. H.
Right arrow Articles by Gibson, J. M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 51:2629-2636, 2002
© 2002 by the American Diabetes Association, Inc.

Low Circulating Levels of Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Are Closely Associated With the Presence of Macrovascular Disease and Hypertension in Type 2 Diabetes

Adrian H. Heald1, K.W. Siddals2, William Fraser3, William Taylor3, Kalpana Kaushal2, Julie Morris4, Robert J. Young2, Anne White1,5, and J. Martin Gibson1,2

1 Faculty of Medicine, Endocrine Sciences Research Group, University of Manchester, Manchester, U.K.
2 Department of Diabetes and Endocrinology, Salford Royal Hospitals University Trust, Salford, U.K.
3 University Department of Clinical Chemistry, Royal Liverpool University Hospital, Liverpool, U.K.
4 Department of Medical Statistics, South Manchester University Hospitals Trust, Manchester, U.K.
5 School of Biological Sciences, University of Manchester, Manchester, U.K.

The IGF system is increasingly implicated in the development of cardiovascular disease. The effects of circulating IGFs on the vasculature are largely modulated by IGFBPs, which control their access to cell-surface IGF receptors. IGFBP-1 has been proposed as the acute regulator of IGF bioavailability because of its metabolic regulation by glucoregulatory hormones. Posttranslational phosphorylation of IGFBP-1 significantly increases its affinity for IGF-I and therefore represents a further mechanism for controlling IGF bioavailability. We have therefore examined the IGF system and IGFBP-1 phosphorylation status, using specifically developed immunoassays, in a cohort of 160 extensively characterized type 2 diabetic subjects on two occasions 12 months apart. Total IGFBP-1 (tIGFBP-1), which is predominantly highly phosphorylated, was significantly lower in subjects with known macrovascular disease (geometric mean [95% CI], 48.7 µg/l [33.7–63.6]) than in patients with no vascular pathology (80.0 µ g/l [52.2–107]; F = 5.4, P = 0.01). A similar relationship was found for highly phosphorylated IGFBP-1 (hpIGFBP-1) concentration (known macrovascular disease, 45.1 µg/l [35.1–55.2]; no macrovascular disease, 75.8 µg/l [56.2–95.3]; F = 4.8, P = 0.01). Logistic regression showed that for every decrease of 2.73 µg/l in IGFBP-1 concentration, there was a 43% increase in the odds of a subject having macrovascular disease (odds ratio 0.57 [95% CI 0.40–0.83]; P = 0.001). hpIGFBP-1 correlated negatively with systolic blood pressure ({rho} = -0.30, P < 0.01), diastolic blood pressure ({rho} = -0.45, P < 0.001), and mean arterial pressure (MAP) ({rho} = -0.41, P < 0.001). Linear regression modeling showed that 40% of the variance in tIGFBP-1 was accounted for by MAP, triglycerides, and nonesterified fatty acids. In contrast, levels of nonphosphorylated and lesser-phosphorylated IGFBP-1 (lpIGFBP-1) were unrelated to macrovascular disease or hypertension but did correlate positively with fasting glucose concentration ({rho} = 0.350, P < 0.01). tIGFBP-1 concentrations were higher in subjects treated with insulin alone (n = 29) than for any other group. This effect persisted after adjustment of tIGFBP-1 levels for BMI, C-peptide, age, and sex (F = 6.5, P < 0.001, {rho} = - 0.46). Such an effect was not apparent for lpIGFBP-1. We conclude that low circulating levels of hpIGFBP-1 are closely correlated with macrovascular disease and hypertension in type 2 diabetes, whereas lpIGFBP-1 isoforms are associated with glycemic control, suggesting a dual role for IGFBP-1 in the regulation of IGF actions in type 2 diabetes. Our data suggest that high circulating concentrations of highly phosphorylated IGFBP-1 may protect against the development of hypertension and cardiovascular disease by reducing the mitogenic potential of IGFs on the vasculature.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
M. Wallander, A. Norhammar, K. Malmberg, J. Ohrvik, L. Ryden, and K. Brismar
IGF Binding Protein 1 Predicts Cardiovascular Morbidity and Mortality in Patients With Acute Myocardial Infarction and Type 2 Diabetes
Diabetes Care, September 1, 2007; 30(9): 2343 - 2348.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. H. Stephens, P. McElduff, A. H. Heald, J. P. New, J. Worthington, W. E. Ollier, and J. M. Gibson
Polymorphisms in IGF-Binding Protein 1 Are Associated With Impaired Renal Function in Type 2 Diabetes
Diabetes, December 1, 2005; 54(12): 3547 - 3553.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. F. Liew, S. D. Wise, K. P. Yeo, and K. O. Lee
Insulin-Like Growth Factor Binding Protein-1 Is Independently Affected by Ethnicity, Insulin Sensitivity, and Leptin in Healthy, Glucose-Tolerant Young Men
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1483 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
K. Kaushal, A. H. Heald, K. W. Siddals, M. S. Sandhu, D. B. Dunger, J. M. Gibson, and N. J. Wareham
The Impact of Abnormalities in IGF and Inflammatory Systems on the Metabolic Syndrome
Diabetes Care, November 1, 2004; 27(11): 2682 - 2688.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. Delafontaine, Y.-H. Song, and Y. Li
Expression, Regulation, and Function of IGF-1, IGF-1R, and IGF-1 Binding Proteins in Blood Vessels
Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): 435 - 444.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. A. Laughlin, E. Barrett-Connor, M. H. Criqui, and D. Kritz-Silverstein
The Prospective Association of Serum Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-1 Levels with All Cause and Cardiovascular Disease Mortality in Older Adults: The Rancho Bernardo Study
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 114 - 120.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. B. Wheatcroft, M. T. Kearney, A. M. Shah, D. J. Grieve, I. L. Williams, J. P. Miell, and P. A. Crossey
Vascular Endothelial Function and Blood Pressure Homeostasis in Mice Overexpressing IGF Binding Protein-1
Diabetes, August 1, 2003; 52(8): 2075 - 2082.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
E. Conti, D. Pitocco, E. Capoluongo, C. Zuppi, G. Ghirlanda, F. Crea, and F. Andreotti
IGF-1 and Macrovascular Complications of Diabetes: Alternative interpretations of recently published data
Diabetes Care, May 1, 2003; 26(5): 1653 - 1654.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
E. S. Leinonen, P. J. Leinonen, and M.-R. Taskinen
IGF Binding Protein-1 and Carotid Intima-Media Thickness in Type 2 Diabetes: Response to Conti et al.
Diabetes Care, May 1, 2003; 26(5): 1654 - 1655.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.